Extended Data Fig. 2: SCNA correlates across tumour types.

a, Scatter plots indicating, for each tumour type, the association between the number of samples and the proportion of the genome affected by subclonal SCNAs. ρ and P values are from Spearman correlation tests. b, Scatter plots showing median purity per tumour versus the proportion of the genome affected by subclonal SCNA. ρ and P values are from Spearman correlation tests. c, Comparing the proportion of the genome affected by clonal and subclonal SCNAs. The median value for each tumour type is indicated. The size of the dots indicates the number of tumours in the corresponding tumour type. Red dots indicate tumour types with significant differences in the proportion of the genome affected by clonal versus subclonal SCNAs. A two-sided Student’s t-test was used to compare proportions of the genome affected by clonal and subclonal SCNAs. a–c, Tumour types with tumour samples from at least 10 patients were included: bladder urothelial carcinoma (BLCA, n = 26), ER⁺ breast cancer (ER+ BRCA, n = 19), HER2⁺ breast cancer (HER2+ BRCA, n = 18), triple-negative breast cancer (TN BRCA, n = 17), colorectal adenocarcinoma (COAD, n = 13), oesophageal adenocarcinoma (ESCA, n = 22), glioma (n = 12), clear cell renal cell carcinoma (KIRC, n = 54), lung adenocarcinoma (LUAD, n = 84), lung squamous cell carcinoma (LUSC, n = 31), prostate adenocarcinoma (PRAD, n = 10), melanoma (SKCM, n = 30) and endometrial carcinoma (UCEC, n = 27). d, The results of the linear regression analysis between LUAD and HER2⁺ breast cancer of the proportion of the genome subject to subclonal SCNAs along with the number of samples from each tumour and the median sample purity for each tumour.